Abu Dhabi Administers UAE’s First Gene Therapy for Blood Disorders

 



Abu Dhabi on January 5, 2026 recorded a milestone for healthcare in the UAE with the first administration of a gene-therapy injection for inherited blood disorders. The therapy, CASGEVY, uses CRISPR-Cas9 gene editing to address the genetic cause of conditions such as sickle cell disease and beta thalassemia, marking a shift from long-term symptom management to targeted correction at the DNA level. The procedure was delivered through a collaboration involving Yas Clinic – Khalifa City, the Abu Dhabi Stem Cells Center (ADSCC), and Vertex Pharmaceuticals, under oversight of the Department of Health – Abu Dhabi (DoH).

CASGEVY Marks Shift From Supportive Care to Genetic Correction

For decades, inherited blood disorders have largely been managed through supportive interventions such as regular transfusions, iron chelation, and pain control. CASGEVY represents a different approach by aiming to correct the underlying genetic fault rather than repeatedly treating downstream effects. For patients and families, this raises the prospect of fewer hospital visits, reduced dependence on transfusions, and improved long-term quality of life, subject to eligibility and clinical outcomes.

How the Gene Therapy Process Works in Practice

The approach uses a patient’s own stem cells, which are collected and then edited in controlled laboratory conditions. CRISPR-Cas9 acts like molecular scissors, targeting and modifying specific DNA segments associated with disease. The corrected cells are then returned to the patient, where they can repopulate the bone marrow and begin producing healthier blood cells over time. This autologous method is designed to reduce rejection risks because the cells originate from the same individual, though it still requires specialist facilities and careful monitoring.

Target Diseases and Wider Implications for Regional Health

The first administration focused on inherited blood disorders with high clinical burden, notably beta thalassemia and sickle cell disease. The rollout also signals broader potential for gene-based interventions in conditions prevalent in the region, including spinal muscular atrophy and haemophilia, where genetic therapies are increasingly being explored or adopted globally. Abu Dhabi’s investment in life sciences, supported by initiatives such as the Emirati Genome Program, has strengthened the clinical infrastructure and data foundations needed for advanced precision medicine.

#GeneTherapy
#GeneticMedicine
#MolecularBiology
#PrecisionMedicine
#GenomeEditing
#CRISPR
#Biotechnology
#CellAndGeneTherapy
#MedicalResearch
#FutureOfMedicine

World Cell Biologist Awards: 

Website Link : cellbiologist.org 

Follow Us On : 
Tumblr ; tumblr.ccom/

Comments

Post a Comment

Popular posts from this blog

Uttrakhand Forest Department Establishes Mahabharata Vatika

Image
  The Uttarakhand Forest Department has established two gardens in Haldwani, showcasing plant species referenced in ancient Indian epics. These gardens, named Ramayana Vatika and Mahabharata Vatika, aim to highlight the ecological wisdom embedded in these texts. Mahabharata Vatika Overview Mahabharata Vatika spans one acre and features 37 plant species mentioned in the epic. Chief Conservator of Forests Sanjeev Chaturvedi emphasised the research behind selecting these species. The garden features important plant species such as: Ecological Significance The garden puts stress on the importance of forests as depicted in the Mahabharata. It references the Vana Parva, which discusses tree planting and wildlife conservation . The epic highlights the mutual dependence of tigers and forests, a concept vital to contemporary conservation efforts. Cultural Connections Chaturvedi brought into light that the Mahabharata teaches the spiritual significance of planting trees. He mentioned Bhish...
Read more

What is Zolgensma?

Image
  Spinal Muscular Atrophy (SMA) is a rare genetic disease affecting muscle function. In India, treatment options are limited, mainly due to high costs. The gene therapy drug, Zolgensma , costs around 16 crore rupees. Despite this, some families are finding ways to access treatment. About Spinal Muscular Atrophy (SMA) SMA is a genetic disorder that leads to the loss of motor neurons in the spinal cord. This results in muscle weakness and atrophy. Symptoms often appear in infancy. Children may struggle with basic movements like lifting their heads or crawling. Early diagnosis is crucial for effective treatment. About Zolgensma Zolgensma (onasemnogene abeparvovec-xioi) is a revolutionary gene therapy for SMA. It addresses the root cause by replacing the missing or defective SMN1 gene . This therapy can improve motor function in affected children. Although it is costly, it represents hope for many families. SMA is not as rare as once thought. The global prevalence is estimated at 1 in ...
Read more

CAR T-Cell Therapy for Cancer

Image
  India has recently made strides in cancer treatment with the introduction of CAR T-cell therapy . The results from the first clinical trials have been published in The Lancet, showcasing a remarkable success rate. This therapy is a game changer for patients with blood cancers. It offers hope to those who have exhausted other treatment options. What is CAR T-Cell Therapy? CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is an innovative treatment that harnesses the body’s immune system. It trains T-cells to target and destroy cancer cells. This therapy is specifically designed for certain blood cancers. It is particularly beneficial for patients whose cancer has relapsed or failed to respond to standard treatments. Clinical Trial The clinical trials reported a response rate of nearly 73%. This indicates that number of patients benefited from the treatment. The trials also provided critical data on survival rates for patients with acute lymphoblastic leukaemia and l...
Read more